Mutant cell surface receptors as targets for individualized cancer diagnosis and therapy

Current Cancer Drug Targets

Volumn 1, Issue 2, 2001, Pages 121-128

  Decker, Karl Friedrich ^a,c   Hofler, Heinz ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL SURFACE RECEPTOR;

GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MUTATION; REVIEW; STOMACH TUMOR;

CADHERINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS;

EID: 0035428063     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334205     Document Type: Article

References (53)

1. Fitzgerald, D. Therapy Targeted to Surface Antigens and Receptors. Sem. Cancer Biol. 1995, 6, 257.
2. Kihara, A, Pastan I. Cytotoxic Activity of Chimeric Toxins Containing the Epidermal Growth Factor-Like Domain of Heregulins Fused to PE38KDEL, a Truncated Recombinant Form of Pseudomonas Exotoxin. Cancer Res. 1995, 55, 71-77.
3. Carpenter, G. EOF: New Tricks for an Old Growth Factor. Curr. Opin. Cell. Biol. 1993,5, 261-264.
4. LeMaistre, C. F.; Meneghetti, C.; Howes, L.; Osborne, C. K. Targeting the EGF Receptor in Breast Cancer Treatment. Breast Cancer Res. Treat. 1994, 32, 97-103.
5. Strom, T. B.; Keiley, V.R.; Murphy, J. R.; Nichols, J.; Woodworth, T. G. Interleukin-2 Receptor-Directed Therapies: Antibody- or Cytokine-Based Targeting Molecules. Anmi. Rev. Med. 1993, 44, 343-353.
6. Waldmann, T. A.; Pastan, I. H.; Gansow, 0. A.; Junghans, R. P. The Multichain Interleukin-2 Receptor: A Target for Immunotherapy. Ann. Intern. Med. 1992, 116, 148-60.
7. Czerwinski, G.; Tarasova, N. I.; Michejda, C. J. Cytotoxic Agents Directed to Peptide Hormone Receptors: Defining Therequirements for a Successful Drug. Proc. Nail. Acad. Sei. USA 1998,95, 11520-11525.
8. Okamoto, S.; Yoshikawa, K.; Obata, Y.;Shibuya, M.; Aoki, S.; Yoshida, J.; Takahashi, T. Monoclonal Antibody Against the Fusion Junction of a DeletionMutant Epidermal Growth Factor Receptor. British J. Cancer 1996, 73, 1366-1372.
9. Wikstrand, C. J.; Hale, L. P.; Batra, S. K.; Hill, M. L. Humphrey, P. A.; Kurpad, S. N.; McLendon, R. E. Moscatello, D.; Pegram, C. N.; Reist, C. J.; Traweek, S. Wong, A.; Zalutsky, M.; Bigner, D. Monoclonal Antibodies against EGFRvIII are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas. Cancer Res. 1995, 55, 3140-3148.
10. Hills, D.; Rowlinson-Busza, G.; Gullick, W. Specific Targeting of A Mutant, Activated EGF Receptor Found in Glioblastoma Using a Monoclonal Antibody. Int. J. Cancer 1995, 63, 537-543.
11. Hudziak, R. M.; Schlessinger, J.; Ullrich, A. Increased Expression of the Putative Growth Factor Receptor pl85HER2 Causes Transformation and Tumorigenesis of NIH 3T3 Cells. Proc. Natl. Acad. Sei. USA 1987,84, 7159-7163.
12. Carter, P.; Presta, L.; Gorman, C. M.; Ridgway, J. B.; Henner, D.; Wong, W. L.; Rowland, A. M.; Kotts, C.; Carver, M. E.; Shepard, H. M. Humanization of an Antipi 85HER2 Antibody for Human Cancer Therapy. Proc. Natl. Acad. Sei. USA 1992, 89, 4285-4289.
13. Nabholtz, J. M.; Slamon, D. New Adjuvant Strategies for Breast Cancer: Meeting the Challenge of Integrating Chemotherapy and Trastuzumab (Herceptin). Semin. Oncol. 2001, 28(1 Suppl 3), 1-12.
14. Slamon, D.; Pegram, M. Rationale for Trastuzumab (Herceptin) In Adjuvant Breast Cancer Trials. Semin. Oncol. 2001, 28(1 Suppl 3), 13-19.
15. Cobleigh, M. A., Vogel, C. L.; Tripathy, D.; Robert, N. J.; Scholl. S.; Fehrenbacher, L.;WoIter, J. M.; Paton, V.; Shak, S.; Lieberman, G.; Slamon, D. J. Multinational Study of the Efficacy and Safety of Humanized AntiHER2 Monoclonalantibody In Women Who have HER2-Overexpressing Metastatic Breast Cancer that has Progressed after Chemotherapy for Metastatic Disease. J. Clin. Oncol. 1999,17, 2639-2648.
16. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. N. Engl. J. Med. 2001,344, 783-792.
17. Leget, G. A.; Czuczman, M. S. Use of Rituximab, the New PDA-Approved Antibody. Curr. Opin. Oncol. 1998,10, 548-551.
18. Eisenhauer, E. A. From the Molecule to the Clinic-Inhibiting HER2 to Treat Breast Cancer. N. Engl. J. Med. 2001,344, 841-842.
19. Laurén, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type of Carcinoma. Acta Pathol. Microbiol. Scand. 1965, 64, 31-49.
20. Thompson, G. B.; Heerden, J. A.; Sarr, M. G. Adenocarcinoma of the Stomach: Are We Making Progress? Lancet 1993,342, 713-718.
21. Wright PA, Williams GT: Molecular Biology and Gastric Carcinoma. Gut 1993, 34,145-147.
22. Tahara, E. Molecular Mechanism of Stomach Carcinogenesis. J. Cancer. Res. Clin. Oncol. 1993,119, 265-272.
23. Tahara, E. Genetic Alterations in Human Gastrointestinal Cancers. Cancer 1995, 75, 1410-1417.
24. Correa, P, Shiao, Y.-H. Phenotypic and Genotypic Events in Gastric Carcinogenesis. Cancer Res. 1994, 54(Suppl), 194 Is-1943s.
25. Stemmermann, G.; Heffelfinger, S. C.; Noffsinger, A.; Hui, Y. Z.; Miller, M. A.; Fenoglio-Preiser, C. M. The Molecular Biology of Esophageal and Gastric Cancer and their Precursors: Oncogenes, Tumor Suppressor Genes, and Growth Factors. Hum. Pathol. 1994, 25, 968-981.
26. Fuchs, C. S.; Mayer, R. J. Gastric Carcinoma. N. Engl. J. Med. 1995, 333, 32-41.
27. Werner, M.; Becker, K. F.; Keller, G.; Hofier, H. Gastric Adenocarcinoma: Pathomorphology and Molecular Pathology. J. Cancer. Res. Clin. Oncol. 2001, 727, 207216.
28. Hedrick, L.; Cho, K. R.; Vogelstein, B. Cell Adhesion Molecules as Tumor Suppressors. Trends Cell Biol. 1993, 3, 36-39.
29. Takeichi, M. Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator. Science 1991, 257, 14511457.
30. Grunwald, G. B. The Structural and Functional Analysis of Cadherin Calcium-Dependent Cell Adhesion Molecules. Curr. Opln. Cell Biol.1993, 5, 797-805.
31. Shapiro, L.; Fannon, A. M.; Kwong, P. D.; Thompson, A.; Lehmann, M. S.; Grubel, G.; Legrand, J. F.; AlsNielsen, J.; Colman, D. R.; Hendrickson, W. A. Structural Basis of Cell-Cell Adhesion by Cadherins. Nature 1995, 374, 327-337.
32. Nagar, B.; Overduin, M.; Ikura, M.; Rini, J. M. Structural Basis of Calcium-Induced E-Cadherin Rigidification and Dimerization. Nature 1996, 380, 360-364.
33. Behrens, J.; Mareel, M. M.; Van Roy, F. M.; Birchmeier, W. Dissecting Tumor Cell Invasion: Epithelial Cells Acquire Invasive Properties after the Loss of Uvomorulin-Mediated Cell-Cell Adhesion. J. Cell Biol. 1989,108, 2435-2447.
34. Frixen, U. H.; Behrens, J.; Sachs, M.; Eberle.vG.; Voss, B.; Warda, A.; Lochner, D.; Birchmeier, W. E-CadherinMediated Cell-Cell Adhesion Prevents Invasiveness of Human Carcinoma Cells. J. Cell Biol. 1991, 113, 173185.
35. VIeminckx, K.; Vakaet, J. L.; Mareel, M.; Fiers, W, Van Roy. F. Genetic Manipulation of E-Cadherin Expression by Epithelial Tumor Cells Reveals an Invasion Suppressor Role. Cell 1991, 66, 107-119.
36. Hirohashi, S. Inactivation of The E-Cadherin-Mediated Cell Adhesion System in Human Cancers. Am. J. Pathol. 1998,153, 333-339.
37. Mayer, B.; Johnson, J. P.; Leitl, F.; Jauch, K.W.; Heiss, M. M.; Schildberg, F. W.; Birchmeier, W.; Funke, I. ECadherin Expression in Primary and Metastatic Gastric Cancer: Down-Regulation Correlates with Cellular Dedifferention and Glandular Disintegration. Cancer Res. 1993, 53, 1690-1695.
38. Shimoyama, Y.; Hirohashi, S. Expression of E- and PCadherin in Gastric Carcinomas. Cancer Res. 1991,57, 2185-2192.
39. Berx, G.; Becker, K. F.; Hofier, H.; van Roy, F. Mutations of the Human E-Cadherin (CDH1) Gene. Hum. Mutât. 1998,12, 226-237.
40. Becker, L; Becker, K.-F.; Röhrl, M. H.; Minkus, G.; Schütze, K.; Hofier, H. Single-Cell Mutation Analysis of Tumors From Stained Histologie Slides. Lab. Invest. 1996, 75, 801-807.
41. Muta, H.; Noguchi, M.; Kanai, Y.; Ochiai, A.; Nawata, H.; Hirohashi, S. E-Cadherin Gene Mutations in Signet Ring Cell Carcinoma of the Stomach. Jpn. J. Cancer Res. 1996, 87, 843-848.
42. Becker, K.-F.; Höfler, H. Frequent Somatic Allelic Inactivation of the E-Cadherin Gene in Gastric Carcinomas. J. Natl. Cancer Inst. 1995,87, 1082-1084.
43. Bevan, S.; Houlston, R. S. Genetic Predisposition to Gastric Cancer. QJM 1999, 92, 5-10.
44. Guilford, P.; Hopkins, J.; Harraway, J.; McLeod, M.; McLeod, N.; Harawira, P.; Taite, H.; Scoular, R.; Miller, A.; Reeve, A. E. E-Cadherin Germline Mutations in Familial Gastric Cancer. Nature 1998, 392, 402-405.
45. Caldas, C.; Carneiro, F.; Lynch, H. T.; Yokota, J.; Wiesner, G. L.; Powell, S. M.; Lewis, F. R.; Huntsman, D. G.; Pharoah, P. D.; Jankowski, J. A.; MacLeod, P.;Vogelsang, H.; Keller, G.; ParkK, G.; Richards, F. M.; Mäher, E. R.; Gayther, S. A.; Oliveira, C.; Grehan, N.; Wight, D.; Seruca, R.; Roviello, F.; Ponder, B. A.; Jackson, C. E. Familial Gastric Cancer: Overview and Guidelines for Management. J. Med. Genet. 1999, 36, 873-880.
46. Guilford, P. J.; Hopkins, J. B.; Grady, W. M.; Markowitz, S. D.; Willis, J.; Lynch, H.; Rajput, A.; Wiesner, G. L.; Lindor, N. M.; Burgart, L. J.; Toro, T. T.; Lee; D.; Limacher, J. M.; Shaw, D. W.; Findlay, M. P.; Reeve, A. E. E-Cadherin Germline Mutations Define an Inherited Cancer Syndrome Dominated by Diffuse Gastric Cancer. Hum Mutât. 1999, 14, 249-255.
47. Ramaekers F, Haag D, Jap P, Vooijs PG. Immunochemical demonstration of keratin and vimentin in cytologie aspirates. Acta Cytol. 1984, 28, 385-392.
48. Ninomiya, I.; Yonemura, Y.; Endo, Y. Detection of ECadherin mRNA from Preoperative Peritoneal Cavity Washings as Diagnosis of Peritoneal Metastasis of Gastric Cancer. In Proceedings of the 1st International Gastric Cancer Congress, Kyoto, Japan; Nishi, M.; Sugano, H.; Takahashi, T., Eds.; Monduzzi Editore: Bologna, 1995, pp. 795-799.
49. Schuhmacher, C.; Becker, K. F.; Reich, U.; Schenk, U.; Mueller, J.; Siewert, J. R.; Hofier, H. Rapid Detection of Mutated E-Cadherin in Peritoneal Lavage Specimens from Patients with Diffuse-Type Gastric Carcinoma. Diagn. Mol. Pathol. 1999, 8, 66-70.
50. Vollmers, H. P.; Zimmermann, U.; Krenn, V.; Timmermann, W.; liiert, B.; Hensel. F.; Hermann, R.; Thiede, A.;Wilhelm, M.; Ruckle-Lanz, H.; Reindl.L.; MullerHermelink, H. K. Adjuvant Therapy for Gastric Adenocarcinoma with the Apoptosis-Inducing Human Monoclonal Antibody SC-1: First Clinical and Histopathological Results. Oncol. Rep. 1998,5, 549552.
51. Handschuh, G.; Candidus, S.; Luber, B.; Reich, U.; Schott, C.; Oswald, S.; Becke, H.; Hutzler, P.; Birchmeier, W.; Hofler, H.; Becker, K. F. TumourAssociated E-Cadherin Mutations Alter Cellular Morphology, Decreasecellular Adhesion and Increase Cellular Motility. Oncogens 1999,18, 4301-4312.
52. Becker, K. F.; Kremmer, E.; Eulitz, M.; Becker, I.; Handschuh, G.; Schuhmacher, C.; Müller, W.; Gabbert, H. E.; Ochiai, A.; Hirohashi S.; Höfler, H. Analysis of ECadherin in Diffuse-Type Gastric Cancer Using a Mutation-Specific Monoclonal Antibody. Am. J. Pathol. 1999,155, 1803-1809.
53. Senekowitsch-Schmidtke, R.; Schuhmacher, C.; Becker, K. F.; Nikula T. K.; Seidl C.; Becker, I.; Miederer, M.; Apostolidis, C.; Adam, C.; Huber, R.; Kremmer, E.; Fischer K.; Schwaiger, M. Highly Specific Tumor Binding of a 213Bi-Labeled Monoclonal Antibody against Mutant E-Cadherin Suggests its Usefulness for Locoregional Alpha-Radioimmunotherapy of DiffuseType Gastric Cancer. Cancer Res. 2001, 61, 2804-2808.